UltraTech Cement in focus after commissioning a bulk terminal in Maharashtra

UltraTech Cement after market hours on Friday, 28 August 2015 said it has commissioned a bulk terminal with a capacity of 2 MTPA in Pune, Maharashtra.

Sun Pharmaceutical Industries will be watched. With regard to news item titled "A class action suit filed against a Sun Pharma subsidiary arm Caraco Pharmaceutical Laboratories in US by workers", Sun Pharmaceutical Industries clarified after market hours on Friday, 28 August 2015 that the aforesaid news item is regarding a decision from the 6th US Circuit Court of Appeals in a class action lawsuit by some former employees of the company's US subsidiary company in US following the shut down of company's subsidiary's Michigan facility. Sun Pharmaceutical Industries said that there is no material impact of the said judgement on the operations/performance of the company.

Bharti Airtel will be in focus. With regard to recent media reports that the company has revived plans to sell its Sri Lanka and Bangladesh operations, Bharti Airtel after market hours on Friday, 28 August 2015, clarified that the company keeps evaluating various opportunities on an ongoing basis in the ordinary course of business and that the company will make necessary disclosures as and when required. According to media reports, Bharti Airtel is planning to sell its Sri Lanka and Bangladesh operations as part of broader plan to consolidate its operations, reduce debt and get out of unproductive, low-margin business. According to the reports, Airtel will separately look at selling its towers business in Sri Lanka and Bangladesh. Bharti Airtel has about 2,500 telecom towers of Sri Lanka and 4,000 in Bangladesh, according to reports.

Aurobindo Pharma on Saturday, 29 August 2015 said that it has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Raloxifene Hydrochloride Tablets USP 60mg. The approved abbreviated new drug application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Evista Tablets 60mg of Eli Lilly. Raloxifene Hydrochloride Tablets are indicated for treatment and prevention of osteoporosis in postmenopausal women. The product has an estimated market size of $404 million in the United States for the twelve months ended June 2015 according to IMS data.

Granules India after market hours on Friday, 28 August 2015 said that it has allotted 40.95 lakh warrants on preferential allotment basis to Mr. C. Krishna Prasad, Chairman and Managing Director and Promoter of the company at a price of Rs 84.91 per warrant after receipt of subscription money being 25% of warrant price. The company will allot equity shares of face value of Re 1 each on receipt of balance 75% warrant price on each warrant within eighteen months from 28 August 2015, Granules India said.

Powered by Capital Market - Live News